https://scholars.lib.ntu.edu.tw/handle/123456789/565652
標題: | Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia | 作者: | Ooi C.J. Hilmi I. Banerjee R. Chuah S.W. Ng S.C. SHU-CHEN WEI Makharia G.K. Pisespongsa P. Chen M.H. Ran Z.H. Ye B.D. Park D.I. Ling K.L. Ong D. Ahuja V. Goh K.L. Sollano J. Lim W.C. Leung W.K. Ali R.A.R. Wu D.C. Ong E. Mustaffa N. Limsrivilai J. Hisamatsu T. Yang S.K. Ouyang Q. Geary R. De Silva J.H. Rerknimitr R. Simadibrata M. Abdullah M. Leong R.W. |
關鍵字: | Adalimumab; Colitis; Crohn disease; Inflammatory bowel disease; Infliximab; ulcerative | 公開日期: | 2019 | 出版社: | Korean Association for the Study of Intestinal Diseases | 卷: | 17 | 期: | 3 | 起(迄)頁: | 285-310 | 來源出版物: | Intestinal Research | 摘要: | This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The Asia-Pacific Working Group on inflammatory bowel disease (IBD) was established in Cebu, Philippines, under the auspices of the Asian Pacific Association of Gastroenterology with the goal of improving IBD care in Asia. This consensus is carried out in collaboration with Asian Organization for Crohn's and Colitis. With biologic agents and biosimilars becoming more established, it is necessary to conduct a review on existing literature and establish a consensus on when and how to introduce biologic agents and biosimilars in the conjunction with conventional treatments for ulcerative colitis (UC) and Crohn's disease (CD) in Asia. These statements also address how pharmacogenetics influence the treatments of UC and CD and provide guidance on response monitoring and strategies to restore loss of response. Finally, the review includes statements on how to manage treatment alongside possible hepatitis B and tuberculosis infections, both common in Asia. These statements have been prepared and voted upon by members of IBD workgroup employing the modified Delphi process. These statements do not intend to be all-encompassing and future revisions are likely as new data continue to emerge. (Intest Res 2019;17:285-310) ? 2019. Korean Association for the Study of Intestinal Diseases. All Rights Reserved. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85074733082&doi=10.5217%2fir.2019.00026&partnerID=40&md5=c7ddce3524f0cd7076e3fb3467a79eb6 https://scholars.lib.ntu.edu.tw/handle/123456789/565652 |
ISSN: | 1598-9100 | DOI: | 10.5217/ir.2019.00026 |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。